Baidu
map

血液科指南

订阅

MedSci主页 / 所有栏目 / 血液科指南

2018 印度专家共识：淋巴瘤的管理

2018-07-30 国外血液科相关专家小组 Indian J Hematol Blood Transfus. 2018 Jul;34(3):39

淋巴瘤

淋巴瘤的临床进程主要取决于疾病的活跃度和侵袭性，淋巴瘤的最佳治疗需要基于正确的诊断以及分类。本文的主要目的是为临床医生针对年龄＞18岁成人淋巴瘤患者的临床管理提供指导。主要内容涉及弥漫性大B细胞淋巴瘤，霍奇金淋巴瘤，滤泡性淋巴瘤，T细胞淋巴瘤，慢性淋巴细胞白血病/小淋巴细胞淋巴瘤，伯基特淋巴瘤和间变性大细胞淋巴瘤的详细治疗方案。

中文标题：

2018 印度专家共识：淋巴瘤的管理

英文标题：

Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group.

发布机构：

国外血液科相关专家小组

发布日期：

2018-07-30

简要介绍：

淋巴瘤的临床进程主要取决于疾病的活跃度和侵袭性，淋巴瘤的最佳治疗需要基于正确的诊断以及分类。本文的主要目的是为临床医生针对年龄＞18岁成人淋巴瘤患者的临床管理提供指导。主要内容涉及弥漫性大B细胞淋巴瘤，霍奇金淋巴瘤，滤泡性淋巴瘤，T细胞淋巴瘤，慢性淋巴细胞白血病/小淋巴细胞淋巴瘤，伯基特淋巴瘤和间变性大细胞淋巴瘤的详细治疗方案。 

拓展指南：与淋巴瘤相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 印度专家共识：淋巴瘤的管理)] GetToolGuiderByIdResponse(projectId=1, id=e19b41c0016335f8, title=2018 印度专家共识：淋巴瘤的管理, enTitle=Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group., guiderFrom=Indian J Hematol Blood Transfus. 2018 Jul;34(3):39, authorId=null, author=, summary=淋巴瘤的临床进程主要取决于疾病的活跃度和侵袭性，淋巴瘤的最佳治疗需要基于正确的诊断以及分类。本文的主要目的是为临床医生针对年龄＞18岁成人淋巴瘤患者的临床管理提供指导。主要内容涉及弥漫性大B细胞淋巴瘤，霍奇金淋巴瘤，滤泡性淋巴瘤，T细胞淋巴瘤，慢性淋巴细胞白血病/小淋巴细胞淋巴瘤，伯基特淋巴瘤和间变性大细胞淋巴瘤的详细治疗方案。 , cover=, journalId=null, articlesId=null, associationId=971, associationName=国外血液科相关专家小组, associationIntro=null, copyright=0, guiderPublishedTime=Mon Jul 30 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>淋巴瘤的临床进程主要取决于疾病的活跃度和侵袭性，淋巴瘤的最佳治疗需要基于正确的诊断以及分类。本文的主要目的是为临床医生针对年龄＞18岁成人淋巴瘤患者的临床管理提供指导。主要内容涉及弥漫性大B细胞淋巴瘤，霍奇金淋巴瘤，滤泡性淋巴瘤，T细胞淋巴瘤，慢性淋巴细胞白血病/小淋巴细胞淋巴瘤，伯基特淋巴瘤和间变性大细胞淋巴瘤的详细治疗方案。 </div> <div><br> </div>拓展指南：<strong>与<font color=red>淋巴瘤</font>相关指南：</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=2ffa51c00162911a" title="2018 ILROG指南：中枢神经系统淋巴瘤放射治疗" target=_blank>2018 ILROG指南：中枢神经系统淋巴瘤放射治疗</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=33dd01c0016288a6" title="NCCN临床实践指南：巨球蛋白血症/淋巴浆细胞性淋巴瘤（2019.V1）" target=_blank>NCCN临床实践指南：巨球蛋白血症/淋巴浆细胞性淋巴瘤（2019.V1）</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=8501f1c00162e883" title="NCCN临床实践指南：T细胞淋巴瘤（2018.V5）" target=_blank>NCCN临床实践指南：T细胞淋巴瘤（2018.V5）</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=6ca7b1c001626ec1" title="NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2019.V1）" target=_blank>NCCN临床实践指南：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（2019.V1）</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=d28911c001608ef9" title="《中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的诊断与治疗指南(2018年版)》解读" target=_blank>《中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的诊断与治疗指南(2018年版)》解读</a></li> 更多信息请点击：<a href="//m.capotfarm.com/guideline/list.do?q=%E6%B7%8B%E5%B7%B4%E7%98%A4" target=_blank>有关淋巴瘤更多指南</a></ul>, tagList=[TagDto(tagId=412, tagName=淋巴瘤)], categoryList=[CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4182, appHits=87, showAppHits=0, pcHits=2766, showPcHits=1771, likes=84, shares=5, comments=14, approvalStatus=1, publishedTime=Wed Aug 29 23:09:59 CST 2018, publishedTimeString=2018-07-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Aug 29 23:09:59 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 13:09:17 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 印度专家共识：淋巴瘤的管理)])
2018 印度专家共识：淋巴瘤的管理
下载请点击：
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=362736, encodeId=eb5e362e36c8, content=下载的存在哪里的？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38b92568268, createdName=12579d04m01暂无昵称, createdTime=Sat Mar 16 10:32:28 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344222, encodeId=e860344222bb, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:07:01 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344221, encodeId=74943442213e, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:06:58 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344220, encodeId=75e134422007, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:06:54 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344219, encodeId=2a5e34421982, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:06:51 CST 2018, time=2018-09-10, status=1, ipAttribution=)]
    2019-03-16 12579d04m01暂无昵称

    下载的存在哪里的？

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=362736, encodeId=eb5e362e36c8, content=下载的存在哪里的？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38b92568268, createdName=12579d04m01暂无昵称, createdTime=Sat Mar 16 10:32:28 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344222, encodeId=e860344222bb, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:07:01 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344221, encodeId=74943442213e, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:06:58 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344220, encodeId=75e134422007, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:06:54 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344219, encodeId=2a5e34421982, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:06:51 CST 2018, time=2018-09-10, status=1, ipAttribution=)]
    2018-09-10 xiaotao112411

    学习学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=362736, encodeId=eb5e362e36c8, content=下载的存在哪里的？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38b92568268, createdName=12579d04m01暂无昵称, createdTime=Sat Mar 16 10:32:28 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344222, encodeId=e860344222bb, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:07:01 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344221, encodeId=74943442213e, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:06:58 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344220, encodeId=75e134422007, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:06:54 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344219, encodeId=2a5e34421982, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:06:51 CST 2018, time=2018-09-10, status=1, ipAttribution=)]
    2018-09-10 xiaotao112411

    学习学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=362736, encodeId=eb5e362e36c8, content=下载的存在哪里的？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38b92568268, createdName=12579d04m01暂无昵称, createdTime=Sat Mar 16 10:32:28 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344222, encodeId=e860344222bb, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:07:01 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344221, encodeId=74943442213e, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:06:58 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344220, encodeId=75e134422007, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:06:54 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344219, encodeId=2a5e34421982, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:06:51 CST 2018, time=2018-09-10, status=1, ipAttribution=)]
    2018-09-10 xiaotao112411

    学习学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=362736, encodeId=eb5e362e36c8, content=下载的存在哪里的？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38b92568268, createdName=12579d04m01暂无昵称, createdTime=Sat Mar 16 10:32:28 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344222, encodeId=e860344222bb, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:07:01 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344221, encodeId=74943442213e, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:06:58 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344220, encodeId=75e134422007, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:06:54 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344219, encodeId=2a5e34421982, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/05/dc628308c49d4aa82335673176ebb6d3.jpg, createdBy=153c1955083, createdName=xiaotao112411, createdTime=Mon Sep 10 00:06:51 CST 2018, time=2018-09-10, status=1, ipAttribution=)]
    2018-09-10 xiaotao112411

    学习学习学习

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

淋巴瘤18 F-FDG PET／CT显像临床应用指南(2016版)

中华医学会核医学分会(CSNM,Chinese Society of Nuclear Medicine) · 2016-10-01

2016 CCO实践指南：利妥昔单抗治疗淋巴瘤和慢性淋巴细胞白血病

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2016-10-13

2014 脂质体阿霉素治疗恶性淋巴瘤及多发性骨髓瘤的中国专家共识

中国抗癌协会临床肿瘤学协作专业委员会(CSCO,Chinese Society of Clinical Oncology) · 2014-12-30

Baidu
map
Baidu
map
Baidu
map